Cargando…

Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients

As a new beta amyloid (Aβ) positron emission tomography (PET) tracer, (18)F-FC119S has shown higher cortical uptake in patients with Alzheimer's disease (AD) than that in healthy control subjects without adverse effects in a previous preliminary study. The aim of this study was to compare (18)F...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Byung Hyun, Kim, Byung Il, Park, Su Yeon, Ko, In Ok, Lee, Kyo Chul, Kim, Kyeong Min, Kim, Yu Kyeong, Lee, Jun-Young, Bu, Seon Hee, Kim, Jung Hwa, Chi, Dae Yoon, Ha, Jeong Ho, Lim, Sang Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371492/
https://www.ncbi.nlm.nih.gov/pubmed/28328855
http://dx.doi.org/10.1097/MD.0000000000006441
_version_ 1782518431730368512
author Byun, Byung Hyun
Kim, Byung Il
Park, Su Yeon
Ko, In Ok
Lee, Kyo Chul
Kim, Kyeong Min
Kim, Yu Kyeong
Lee, Jun-Young
Bu, Seon Hee
Kim, Jung Hwa
Chi, Dae Yoon
Ha, Jeong Ho
Lim, Sang Moo
author_facet Byun, Byung Hyun
Kim, Byung Il
Park, Su Yeon
Ko, In Ok
Lee, Kyo Chul
Kim, Kyeong Min
Kim, Yu Kyeong
Lee, Jun-Young
Bu, Seon Hee
Kim, Jung Hwa
Chi, Dae Yoon
Ha, Jeong Ho
Lim, Sang Moo
author_sort Byun, Byung Hyun
collection PubMed
description As a new beta amyloid (Aβ) positron emission tomography (PET) tracer, (18)F-FC119S has shown higher cortical uptake in patients with Alzheimer's disease (AD) than that in healthy control subjects without adverse effects in a previous preliminary study. The aim of this study was to compare (18)F-FC119S PET and (11)C-PiB PET in healthy control (HC) subjects, mild cognitive impairment (MCI) patients, and AD patients. A total of 48 subjects, including 28 HC subjects, 10 MCI patients, and 10 AD patients, underwent static (18)F-FC119S PET (30 minutes after intravenous [i.v.] injection) and (11)C-PiB PET (40 minutes after i.v. injection) on the same day. Both PET images were visually and quantitatively assessed. Standardized uptake value ratios (SUVRs) were calculated for each brain region using the cerebellar cortex as a reference region. None (0%) of the 28 HC subjects and 4 (40%) of 10 MCI patients had positive scans on both PET images. Of the 10 AD patients, 7 (70%) had positive scans on (11)C-PiB PET while 6 (60%) had positive scans on (18)F-FC119S PET. Overall, 47 (98%) of 48 participants showed identical results based on visual analysis. Cortical SUVR of (18)F-FC119S was higher in AD patients (1.38 ± 0.16), followed by that in MCI patients (1.24 ± 0.10) and in HC subjects (1.14 ± 0.05). Compared with (11)C-PiB PET, (18)F-FC119S PET yielded a higher effect size (d = 2.02 vs. 1.67) in AD patients and a slightly lower effect size (d = 1.26 vs. 1.38) in MCI patients. In HC subjects, the nonspecific binding of (18)F-FC119S to white matter (with the frontal cortex-to-white matter SUV ratio of 0.76) was slightly lower than that of (11)C-PiB (ratio of 0.73). There was a significant linear correlation (slope = 0.41, r = 0.78, P < 0.001) between (11)C-PiB and (18)F-FC119S cortical SUVR. We could safely obtain images similar to (11)C-PiB PET imaging Aβ in the brain using (18)F-FC119S PET. Therefore, (18)F-FC119S might be suitable for imaging Aβ deposition.
format Online
Article
Text
id pubmed-5371492
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-53714922017-04-03 Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients Byun, Byung Hyun Kim, Byung Il Park, Su Yeon Ko, In Ok Lee, Kyo Chul Kim, Kyeong Min Kim, Yu Kyeong Lee, Jun-Young Bu, Seon Hee Kim, Jung Hwa Chi, Dae Yoon Ha, Jeong Ho Lim, Sang Moo Medicine (Baltimore) 6800 As a new beta amyloid (Aβ) positron emission tomography (PET) tracer, (18)F-FC119S has shown higher cortical uptake in patients with Alzheimer's disease (AD) than that in healthy control subjects without adverse effects in a previous preliminary study. The aim of this study was to compare (18)F-FC119S PET and (11)C-PiB PET in healthy control (HC) subjects, mild cognitive impairment (MCI) patients, and AD patients. A total of 48 subjects, including 28 HC subjects, 10 MCI patients, and 10 AD patients, underwent static (18)F-FC119S PET (30 minutes after intravenous [i.v.] injection) and (11)C-PiB PET (40 minutes after i.v. injection) on the same day. Both PET images were visually and quantitatively assessed. Standardized uptake value ratios (SUVRs) were calculated for each brain region using the cerebellar cortex as a reference region. None (0%) of the 28 HC subjects and 4 (40%) of 10 MCI patients had positive scans on both PET images. Of the 10 AD patients, 7 (70%) had positive scans on (11)C-PiB PET while 6 (60%) had positive scans on (18)F-FC119S PET. Overall, 47 (98%) of 48 participants showed identical results based on visual analysis. Cortical SUVR of (18)F-FC119S was higher in AD patients (1.38 ± 0.16), followed by that in MCI patients (1.24 ± 0.10) and in HC subjects (1.14 ± 0.05). Compared with (11)C-PiB PET, (18)F-FC119S PET yielded a higher effect size (d = 2.02 vs. 1.67) in AD patients and a slightly lower effect size (d = 1.26 vs. 1.38) in MCI patients. In HC subjects, the nonspecific binding of (18)F-FC119S to white matter (with the frontal cortex-to-white matter SUV ratio of 0.76) was slightly lower than that of (11)C-PiB (ratio of 0.73). There was a significant linear correlation (slope = 0.41, r = 0.78, P < 0.001) between (11)C-PiB and (18)F-FC119S cortical SUVR. We could safely obtain images similar to (11)C-PiB PET imaging Aβ in the brain using (18)F-FC119S PET. Therefore, (18)F-FC119S might be suitable for imaging Aβ deposition. Wolters Kluwer Health 2017-03-24 /pmc/articles/PMC5371492/ /pubmed/28328855 http://dx.doi.org/10.1097/MD.0000000000006441 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 6800
Byun, Byung Hyun
Kim, Byung Il
Park, Su Yeon
Ko, In Ok
Lee, Kyo Chul
Kim, Kyeong Min
Kim, Yu Kyeong
Lee, Jun-Young
Bu, Seon Hee
Kim, Jung Hwa
Chi, Dae Yoon
Ha, Jeong Ho
Lim, Sang Moo
Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients
title Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients
title_full Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients
title_fullStr Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients
title_full_unstemmed Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients
title_short Head-to-head comparison of (11)C-PiB and (18)F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients
title_sort head-to-head comparison of (11)c-pib and (18)f-fc119s for aβ imaging in healthy subjects, mild cognitive impairment patients, and alzheimer's disease patients
topic 6800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371492/
https://www.ncbi.nlm.nih.gov/pubmed/28328855
http://dx.doi.org/10.1097/MD.0000000000006441
work_keys_str_mv AT byunbyunghyun headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT kimbyungil headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT parksuyeon headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT koinok headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT leekyochul headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT kimkyeongmin headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT kimyukyeong headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT leejunyoung headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT buseonhee headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT kimjunghwa headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT chidaeyoon headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT hajeongho headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients
AT limsangmoo headtoheadcomparisonof11cpiband18ffc119sforabimaginginhealthysubjectsmildcognitiveimpairmentpatientsandalzheimersdiseasepatients